Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 13;55(3):174-181.
doi: 10.2478/enr-2021-0019.

Does dehydroepiandrosterone sulfate have a role in COVID-19 prognosis and treatment?

Sojit Tomo  1 , Mithu Banerjee  1 , Praveen Sharma  1 , Mahendra Garg  2
Affiliations
Free article
Review

Does dehydroepiandrosterone sulfate have a role in COVID-19 prognosis and treatment?

Sojit Tomo et al. Endocr Regul. .
Free article

Abstract

The pathophysiology of COVID comprises an exaggerated pro-inflammatory response. Hypothalamic-pituitary-adrenal (HPA) axis has a crucial role in various inflammatory conditions and modulated immunological response. Limited evidence is available regarding the incidence and the effect of HPA dysfunction in COVID-19. Although the cortisol levels have only been estimated in a few studies, the dehydroepiandrosterone sulfate (DHEAS) release from the adrenal gland has not been explored yet. In this mini review, the authors discuss the role of dehydroepiandrosterone (DHEA) and DHEAS in the acute stress response and immunological modulation. Various effects of DHEAS have been demonstrated in different diseases. The specific inhibitory effect of DHEA on interleukin 6 (IL-6) could be of paramount importance in COVID-19. Further, DHEA supplementation has already been proposed in inflammatory conditions, like rheumatoid arthritis. DHEAS levels in COVID-19 may help to understand the HPA axis dysfunction as well as the possibility of repurposing DHEA as a drug for mitigating the pro-inflammatory COVID-19.

Keywords: COVID-19; DHEA; DHEAS; cortisol; hypothalamic-pituitary-adrenal axis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Andus T, Straub RH, Vogl D et al. Low serum levels of dehydroepiandrosterone sulfate (DHEAS) in Crohn’s disease (CD) and ulcerative colitis (UC). Gastroenterology 110, A855, 1996.
    1. Arlt W, Hammer F, Sanning P, Butcher SK, Lord JM, Allolio B, Annane D, Stewart PM. Dissociation of serum dehydroepiandrosterone and dehydroepiandrosterone sulfate in septic shock. J Clin Endocrinol Metab 91, 2548–2554, 2006.
    1. Arvat E, Di Vito L, Lanfranco F, Maccario M, Baffoni C, Rossetto R, Aimaretti G, Camanni F, Ghigo E. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: Dose-response study. J Clin Endocrinol Metab 85, 3141–3146, 2000.
    1. Auci D, Kaler L, Subramanian S, Huang Y, Frincke J, Reading C, Offner H. A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells. Ann N Y Acad Sci 1110, 630–640, 2007.
    1. Baylis D, Bartlett DB, Syddall HE, Ntani G, Gale CR, Cooper C, Lord JM, Sayer AA. Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people. Age (Dordr) 35, 963–971, 2013.

MeSH terms

Substances

LinkOut - more resources